Jonathan Evans is a Respiratory physician. ClinicalTrials.gov lists 11 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Foden Rd Ste 103
South Portland, ME 041062327
Telephone
207-828-1122Provider last certified this registry record 12 Feb 2024.
Clinical trials
- Investigating the Efficacy of ApplTree on Prospective Memory in Stroke
Sponsor: NHS Greater Glasgow and Clyde
- A Reminder App for Supporting Adherence to Treatment Goals in Parkinson's Disease
Sponsor: NHS Greater Glasgow and Clyde
- Integrated PRocess and StrategieS Training: I-PRESS Training
Sponsor: NHS Greater Glasgow and Clyde
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- JAZZ PHARMACEUTICALS INC.Program year20252 payments
- GENZYME CORPORATIONProgram year20256 payments
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
62.5%Corticosteroid41.9%Trelegy Ellipta65%Breztri Aerosphere22%Breo Ellipta6%Budesonide-Formoterol Fumarate4%Symbicort3%Part D<11 patientsbeta2-Adrenergic Agonist15%Albuterol Sulfate Hfa95%Ventolin Hfa5%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
12.9%Corticosteroid11.5%Prednisone100%Part D≥80 patientsPotassium supplement0.7%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Nervous system
11.9%Nonergot Dopamine Agonist2.5%Ropinirole Hcl59%Pramipexole Dihydrochloride41%Part D<11 patientsBenzodiazepine2.2%Clonazepam62%Temazepam39%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”